Hypofractionated Reirradiation for Recurrent Malignant Glioma

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2009 Feb 26

PMID 19240998

Citations 44

Authors

Guido Henke

Frank Paulsen

Joachim P Steinbach

Ute Ganswindt

Hana Isijanov

Rolf-Dieter Kortmann

Michael Bamberg

Claus Belka

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Treatment options for recurrent high-grade glioma after a complete course of radiotherapy comprise surgery, reirradiation and chemotherapy but the efficacy of any of the given salvage treatments is limited. In order to further define the role of short-term radiotherapy as retreatment option for selected patients, we analyzed outcomes after treatment with a hypofractionated radiation.

Patients And Methods: Treatment outcomes (overall survival and treatment-associated toxicity) were analyzed retrospectively in 31 patients treated between 1994 and 2007. Hypofractionated radiotherapy was performed after three-dimensional CT planning with a median total dose of 20 Gy in a single department.

Results: With a median interval of 20 months from primary radiotherapy, two grade III and 29 grade IV tumors were reirradiated. Pretreatment consisted of surgery and involved-field radiotherapy (median 59 Gy). 77% of the patients received additional chemotherapy before the second course of radiotherapy, and 48% were treated after secondary resection. The median overall survival after hypofractionated radiotherapy was 10.2 months, and the median overall survival time after primary diagnosis 30.9 months. No severe toxicity was observed.

Conclusion: Hypofractionated reirradiation with 20 Gy given over 1 week is a practicable and well-tolerated treatment option for patients with recurrent malignant glioma. The overall survival was comparable to the reported outcomes from other series including those with longer treatment protocols.

Citing Articles

Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study.

Preusser M, Kazda T, Le Rhun E, Sahm F, Smits M, Gempt J Trials. 2024; 25(1):366.

PMID: 38849943 PMC: 11157762. DOI: 10.1186/s13063-024-08213-7.

High-dose re-irradiation of intracranial lesions - Efficacy and safety including dosimetric analysis based on accumulated EQD2Gy dose EQD calculation.

Stiefel I, Schroder C, Tanadini-Lang S, Pytko I, Vu E, Klement R Clin Transl Radiat Oncol. 2021; 27:132-138.

PMID: 33659717 PMC: 7890358. DOI: 10.1016/j.ctro.2021.01.011.

Current status and recent advances in reirradiation of glioblastoma.

Minniti G, Niyazi M, Alongi F, Navarria P, Belka C Radiat Oncol. 2021; 16(1):36.

PMID: 33602305 PMC: 7890828. DOI: 10.1186/s13014-021-01767-9.

Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial.

Wenger K, Wagner M, Harter P, Franz K, Bojunga J, Fokas E Cancers (Basel). 2020; 12(12).

PMID: 33261052 PMC: 7760797. DOI: 10.3390/cancers12123549.

Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis.

Shanker M, Chua B, Bettington C, Foote M, Pinkham M Neurooncol Pract. 2019; 6(2):144-155.

PMID: 31386038 PMC: 6656322. DOI: 10.1093/nop/npy019.

References

Lee S, Fraass B, Marsh L, Herbort K, Gebarski S, Martel M . Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999; 43(1):79-88. DOI: 10.1016/s0360-3016(98)00266-1. View

Shepherd S, Laing R, Cosgrove V, Warrington A, Hines F, Ashley S . Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997; 37(2):393-8. DOI: 10.1016/s0360-3016(96)00455-5. View

Combs S, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D . Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer. 2005; 104(10):2168-73. DOI: 10.1002/cncr.21429. View

Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G . Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol. 2006; 81(3):287-94. DOI: 10.1007/s11060-006-9231-0. View

Larson D, Suplica J, Chang S, Lamborn K, McDermott M, Sneed P . Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2004; 6(2):119-26. PMC: 1871978. DOI: 10.1215/s1152851703000425. View

Vordermark D, Kolbl O, Ruprecht K, Vince G, Bratengeier K, Flentje M . Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005; 5:55. PMC: 1156875. DOI: 10.1186/1471-2407-5-55. View

Grosu A, Weber W, Franz M, Stark S, Piert M, Thamm R . Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 63(2):511-9. DOI: 10.1016/j.ijrobp.2005.01.056. View

Mandl E, Dirven C, Buis D, Postma T, Vandertop W . Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008; 69(5):506-9. DOI: 10.1016/j.surneu.2007.03.043. View

Fahrig A, Ganslandt O, Lambrecht U, Grabenbauer G, Kleinert G, Sauer R . Hypofractionated stereotactic radiotherapy for brain metastases--results from three different dose concepts. Strahlenther Onkol. 2007; 183(11):625-30. DOI: 10.1007/s00066-007-1714-1. View

10.

Paulsen F, Hoffmann W, Becker G, Belka C, Weinmann M, Classen J . Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J Cancer Res Clin Oncol. 1999; 125(7):411-8. DOI: 10.1007/s004320050295. View

11.

Leibel S, Gutin P, Wara W, SILVER P, Larson D, Edwards M . Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 1989; 17(6):1129-39. DOI: 10.1016/0360-3016(89)90518-x. View

12.

Guyotat J, Signorelli F, Frappaz D, Madarassy G, Ricci A, Bret P . Is reoperation for recurrence of glioblastoma justified?. Oncol Rep. 2000; 7(4):899-904. DOI: 10.3892/or.7.4.899. View

13.

Wick A, Felsberg J, Steinbach J, Herrlinger U, Platten M, Blaschke B . Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007; 25(22):3357-61. DOI: 10.1200/JCO.2007.10.7722. View

14.

Dirks P, Bernstein M, Muller P, TUCKER W . The value of reoperation for recurrent glioblastoma. Can J Surg. 1993; 36(3):271-5. View

15.

Kim H, Thornton A, GREENBERG H, Page M, Junck L, Sandler H . Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. Am J Clin Oncol. 1997; 20(4):358-63. DOI: 10.1097/00000421-199708000-00007. View

16.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

17.

Moser R . Surgery for glioma relapse. Factors that influence a favorable outcome. Cancer. 1988; 62(2):381-90. DOI: 10.1002/1097-0142(19880715)62:2<381::aid-cncr2820620225>3.0.co;2-b. View

18.

Kortmann R, Jeremic B, Weller M, Plasswilm L, Bamberg M . Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol. 2003; 179(4):219-32. DOI: 10.1007/s00066-003-1027-y. View

19.

Shrieve D, Alexander 3rd E, Wen P, Fine H, Kooy H, Black P . Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995; 36(2):275-82; discussion 282-4. DOI: 10.1227/00006123-199502000-00006. View

20.

Vredenburgh J, Desjardins A, Herndon 2nd J, Marcello J, Reardon D, Quinn J . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-9. DOI: 10.1200/JCO.2007.12.2440. View